176 related articles for article (PubMed ID: 19502954)
1. Direct thrombin inhibitor prevents delayed graft function in a porcine model of renal transplantation.
Giraud S; Thuillier R; Belliard A; Hebrard W; Nadeau C; Milin S; Goujon JM; Manguy E; Mauco G; Hauet T; Macchi L
Transplantation; 2009 Jun; 87(11):1636-44. PubMed ID: 19502954
[TBL] [Abstract][Full Text] [Related]
2. Thrombin inhibition with melagatran does not attenuate renal ischaemia-reperfusion injury in rats.
Nitescu N; Grimberg E; Ricksten SE; Marcussen N; Guron G
Nephrol Dial Transplant; 2007 Aug; 22(8):2149-55. PubMed ID: 17405786
[TBL] [Abstract][Full Text] [Related]
3. A combination of a thrombin inhibitor and dexamethasone prevents the development of experimental disseminated intravascular coagulation in rats.
Elg M; Gustafsson D
Thromb Res; 2006; 117(4):429-37. PubMed ID: 15869787
[TBL] [Abstract][Full Text] [Related]
4. Treatment with melagatran alone or in combination with thrombolytic therapy reduced ischemic brain injury.
Wang CX; Ding X; Shuaib A
Exp Neurol; 2008 Sep; 213(1):171-5. PubMed ID: 18598697
[TBL] [Abstract][Full Text] [Related]
5. Profibrinolytic activity of the direct thrombin inhibitor melagatran and unfractionated heparin in platelet-poor and platelet-rich clots.
Semeraro F; Piro D; Rossiello MR; Ammollo T; Colucci M
Thromb Haemost; 2007 Dec; 98(6):1208-14. PubMed ID: 18064315
[TBL] [Abstract][Full Text] [Related]
6. The direct thrombin inhibitor melagatran counteracts endotoxin-induced endothelial leukocyte adherence and microvascular leakage in the rat mesentery. Rationale for the treatment of inflammatory disorders beyond sepsis?
Leithäuser B; Fassbender M; Eickhoff M; Elg M; Eichner G; Matthias FR
Clin Hemorheol Microcirc; 2007; 36(4):277-89. PubMed ID: 17502698
[TBL] [Abstract][Full Text] [Related]
7. Melagatran, a low molecular weight thrombin inhibitor, counteracts endotoxin-induced haemodynamic and renal dysfunctions in the pig.
Eriksson M; Larsson A; Saldeen T; Mattsson C
Thromb Haemost; 1998 Dec; 80(6):1022-6. PubMed ID: 9869178
[TBL] [Abstract][Full Text] [Related]
8. Prevention of clot formation during haemodialysis using the direct thrombin inhibitor melagatran in patients with chronic uraemia.
Attman PO
Nephrol Dial Transplant; 2006 Jun; 21(6):1738. PubMed ID: 16364986
[No Abstract] [Full Text] [Related]
9. Three vehicle formulations for melagatran, a direct thrombin inhibitor, evaluated in a vena cava thrombosis model in the rat.
Elg M; Börjesson I; Carlsson S
Biopharm Drug Dispos; 2003 Sep; 24(6):251-7. PubMed ID: 12973822
[TBL] [Abstract][Full Text] [Related]
10. Local proCPU (TAFI) activation during thrombolytic treatment in a dog model of coronary artery thrombosis can be inhibited with a direct, small molecule thrombin inhibitor (melagatran).
Mattsson C; Björkman JA; Abrahamsson T; Nerme V; Schatteman K; Leurs J; Scharpé S; Hendriks D
Thromb Haemost; 2002 Apr; 87(4):557-62. PubMed ID: 12008935
[TBL] [Abstract][Full Text] [Related]
11. Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes.
Gustafsson D; Antonsson T; Bylund R; Eriksson U; Gyzander E; Nilsson I; Elg M; Mattsson C; Deinum J; Pehrsson S; Karlsson O; Nilsson A; Sörensen H
Thromb Haemost; 1998 Jan; 79(1):110-8. PubMed ID: 9459334
[TBL] [Abstract][Full Text] [Related]
12. Melagatran for thromboprophylaxis after mechanical valve implantation: results in a heterotopic porcine model.
Thompson JL; Hamner CE; Potter DD; Lewin M; Sundt TM; Schaff HV
J Thorac Cardiovasc Surg; 2007 Aug; 134(2):359-65. PubMed ID: 17662773
[TBL] [Abstract][Full Text] [Related]
13. The respective and combined anticoagulant effects of recombinant human activated protein C, melagatran and heparins using CAT.
Cimenti C; Koestenberger M; Leschnik B; Haidl H; Muntean W
Thromb Res; 2007; 119(3):361-7. PubMed ID: 16712904
[TBL] [Abstract][Full Text] [Related]
14. Anticoagulant action of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, in umbilical cord and adult plasma: an in vitro examination.
Koestenberger M; Gallistl S; Cvirn G; Baier K; Leschnik B; Muntean W
Thromb Res; 2005; 115(1-2):135-42. PubMed ID: 15567465
[TBL] [Abstract][Full Text] [Related]
15. Detrimental effects of controlled reperfusion on renal function after porcine autotransplantation are fully compensated by the use of Carolina rinse solution.
Wamser P; Asari R; Goetzinger P; Mayer G; Berlakovich G; Soliman T; Muehlbacher F; Steininger R
Transpl Int; 2003 Mar; 16(3):191-6. PubMed ID: 12664215
[TBL] [Abstract][Full Text] [Related]
16. Protective effect of an inhibitor of interleukin-8 (meraxin) from ischemia and reperfusion injury in a rat model of kidney transplantation.
Neri F; Puviani L; Tsivian M; Prezzi D; Pacilé V; Cavallari G; Bertelli R; Bianchi E; Piras GL; Pariali M; Cavalieri B; Bertini R; Faenza A; Nardo B
Transplant Proc; 2007; 39(6):1771-2. PubMed ID: 17692608
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of action of the oral direct thrombin inhibitor ximelagatran.
Mattsson C; Sarich TC; Carlsson SC
Semin Vasc Med; 2005 Aug; 5(3):235-44. PubMed ID: 16123910
[TBL] [Abstract][Full Text] [Related]
18. Prevention of clot formation during haemodialysis using the direct thrombin inhibitor melagatran in patients with chronic uraemia.
Attman PO; Ottosson P; Samuelsson O; Eriksson UG; Eriksson-Lepkowska M; Fager G
Nephrol Dial Transplant; 2005 Sep; 20(9):1889-97. PubMed ID: 15928099
[TBL] [Abstract][Full Text] [Related]
19. A pharmacokinetic study of the combined administration of amiodarone and ximelagatran, an oral direct thrombin inhibitor.
Teng R; Sarich TC; Eriksson UG; Hamer JE; Gillette S; Schützer KM; Carlson GF; Kowey PR
J Clin Pharmacol; 2004 Sep; 44(9):1063-71. PubMed ID: 15317834
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT.
Eriksson H; Eriksson UG; Frison L; Hansson PO; Held P; Holmström M; Hägg A; Jonsson T; Lapidus L; Leijd B; Stockelberg D; Säfwenberg U; Taghavi A; Thorsén M
Thromb Haemost; 1999 Mar; 81(3):358-63. PubMed ID: 10102460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
